Table 1.
Characteristics of the whole study population
| Variable | Whole sample (n = 647) |
|---|---|
| Age (years) |
77.5 ± 0.8 |
| Urine albumin creatinine ratio (mg/mmol) |
4.6 ± 19.4 |
| Serum cystatin C (mg/L) |
1.09 ± 0.28 |
| eGFR* (ml/min/1.73 m2) |
73.6 ± 17.4 |
| Fasting plasma glucose (mmol/L) |
5.9 ± 1.3 |
| Systolic blood pressure (mmHg) |
150.9 ± 20.7 |
| Diastolic blood pressure (mmHg) |
81.3 ± 9.7 |
| Body mass index (kg/m2) |
26.3 ± 3.5 |
| Serum triglyceride (mmol/L) |
1.4 ± 0.6 |
| HDL cholesterol (mmol/L) |
1.3 ± 0.3 |
| LDL cholesterol (mmol/L) |
3.5 ± 0.9 |
| Urine 15-keto-dihydro-PGF2α (nmol/mmol) |
0.32 ± 0.18 |
| Serum interleukin-6 (ng/L) |
3.9 ± 2.7 |
| Serum amyloid A protein (mg/L) |
11.3 ± 43.6 |
| high sensitivity C-reactive protein (mg/L) |
3.8 ± 6.8 |
| Urine F2-isoprostane (nmol/mmol) |
0.20 ± 0.10 |
| Diabetes mellitus – n (%) |
91 (14.1) |
| Smoking – n (%) |
45 (7.0) |
| Dyslipidemia – n (%) |
226 (34.9) |
| Lipid lowering treatment – n (%) |
119 (18.4) |
| Cardiovascular disease – n (%) |
175 (27.1) |
| Hypertension – n (%) |
292 (45.1) |
| Antihypertensive treatment – n (%) |
272 (42.0) |
| ACE-inhibitor – n (%) |
109 (16.9) |
| ASA medicine – n (%) |
193 (29.8) |
| Corticosteroid treatment – n (%) |
26 (4.0) |
| Non-steroidal anti-inflammatory drugs – n (%) | 35 (5.4) |
Data are mean ± SD for continuous variables and n. (%) for dichotomous variables. *eGFR was estimated from cystatin C.